Top

International Journal of Mental Health and Addiction

Published in:

01-02-2020 | Original Article

The Methamphetamine-Associated Psychosis Spectrum: a Clinically Focused Review

Authors: Shalini Arunogiri, Rebecca McKetin, Antonio Verdejo-Garcia, Dan I. Lubman

Published in: International Journal of Mental Health and Addiction | Issue 1/2020

Abstract

Methamphetamine use is a global concern, and methamphetamine-associated psychosis (MAP) is a particular harm resulting from regular use of the drug that causes significant distress and burden on health and social services. This paper aims to provide a clinically focussed and up-to-date overview of the prevalence, risk factors, and clinical and cognitive features of MAP. The prevalence of MAP ranges between 15 and 30% in recreational settings and up to 60% in some inpatient treatment settings, with up to a third of people with MAP later diagnosed with persistent psychotic disorders. The frequency of methamphetamine use and severity of dependence are the most consistent risk factors for MAP, but other predictors such as genetic vulnerability, a family history of psychotic illness, or trauma also play a role. People with MAP can vary in their presentation, from brief delusional experiences, to persistent psychosis characterised by first-rank symptoms and cognitive impairment. Contemporary conceptualisations of MAP need to incorporate this spectrum of clinical presentations in order to inform clinical decision-making, service provision, and research directions.

Alderson, H., Semple, D., Blayney, C., Queirazza, F., Chekuri, V., & Lawrie, S. (2017). Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study. Psychological Medicine, 1–8.

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM-5®): American Psychiatric Pub.

Angrist, B. M., & Gershon, S. (1970). The phenomenology of experimentally induced amphetamine psychosis: preliminary observations. Biological Psychiatry.

Arunogiri, S., Foulds, J. A., McKetin, R., & Lubman, D. I. (2018). A systematic review of risk factors for methamphetamine-associated psychosis. Australian & New Zealand Journal of Psychiatry, 0004867417748750.

Ashok, A. H., Mizuno, Y., Volkow, N. D., & Howes, O. D. (2017). Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry, 74(5), 511–519.PubMedPubMedCentral

Bell, D. (1965). Comparison of amphetamine psychosis and schizophrenia. The British Journal of Psychiatry, 111(477), 701–707.PubMed

Bell, D. S. (1973). The experimental reproduction of amphetamine psychosis. Archives of General Psychiatry, 29(1), 35–40.PubMed

Bouchard, V., Lecomte, T., & Mueser, K. T. (2013). Could cognitive deficits help distinguish methamphetamine-induced psychosis from a psychotic disorder with substance abuse? Mental Health and Substance Use, 6(2), 101–110.

Bousman, C. A., McKetin, R., Burns, R., Woods, S. P., Morgan, E. E., Atkinson, J. H., Grant, I. (2014). Typologies of positive psychotic symptoms in methamphetamine dependence. The American Journal on Addictions.

Bramness, J. G., & Rognli, E. B. (2016). Psychosis induced by amphetamines. Current Opinion in Psychiatry, 29(4), 236–241.PubMed

Breen, M., Uhlmann, A., Nday, C., Glatt, S., Mitt, M., Metsalpu, A., et al. (2016). Candidate gene networks and blood biomarkers of methamphetamine-associated psychosis: an integrative RNA-sequencing report. Translational Psychiatry, 6(5), e802.PubMedPubMedCentral

Callaghan, R. C., Cunningham, J. K., Allebeck, P., Arenovich, T., Sajeev, G., Remington, G., & Kish, S. J. (2012). Methamphetamine use and schizophrenia: a population-based cohort study in California. American Journal of Psychiatry, 169(4), 389–396.

Chen, C. K., Lin, S. K., Sham, P. C., Ball, D., Loh el, W., & Murray, R. M. (2005). Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 136B(1), 87–91.

Chen, C.-K., Lin, S.-K., Chen, Y.-C., Huang, M.-C., Chen, T.-T., Ree, S. C., & Wang, L.-J. (2015). Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug and Alcohol Dependence, 148, 158–164.PubMed

Curran, C., Byrappa, N., & Mcbride, A. (2004). Stimulant psychosis: systematic review. British Journal of Psychiatry, 185(3), 196–204.

Dean, A. C., Groman, S. M., Morales, A. M., & London, E. D. (2013). An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology, 38(2), 259–274.PubMed

Ding, Y., Lin, H., Zhou, L., Yan, H., & He, N. (2014). Adverse childhood experiences and interaction with methamphetamine use frequency in the risk of methamphetamine-associated psychosis. Drug and Alcohol Dependence, 142, 295–300.PubMed

Ezzatpanah, Z., Shariat, S. V., & Tehrani-Doost, M. (2014). Cognitive functions in methamphetamine induced psychosis compared to schizophrenia and normal subjects. Iranian journal of psychiatry, 9(3), 152–157.PubMedPubMedCentral

Garety, P. A., Bebbington, P., Fowler, D., Freeman, D., & Kuipers, E. (2007). Implications for neurobiological research of cognitive models of psychosis: a theoretical paper. Psychological Medicine, 37(10), 1377–1391.PubMed

Gowin, J. L., Stewart, J. L., May, A. C., Ball, T. M., Wittmann, M., Tapert, S. F., & Paulus, M. P. (2014). Altered cingulate and insular cortex activation during risk-taking in methamphetamine dependence: losses lose impact. Addiction, 109(2), 237–247.PubMed

Grant, K. M., LeVan, T. D., Wells, S. M., Li, M., Stoltenberg, S. F., Gendelman, H. E., & Bevins, R. A. (2012). Methamphetamine-associated psychosis. Journal of Neuroimmune Pharmacology, 7(1), 113–139.PubMed

Hides, L., Dawe, S., McKetin, R., Kavanagh, D. J., Young, R. M., Teesson, M., & Saunders, J. B. (2015). Primary and substance-induced psychotic disorders in methamphetamine users. Psychiatry Research, 226(1), 91–96.PubMed

Howes, O., McCutcheon, R., & Stone, J. (2015). Glutamate and dopamine in schizophrenia: an update for the 21st century. Journal of Psychopharmacology, 29(2), 97–115.PubMed

Jacobs, E., Fujii, D., Schiffman, J., & Bello, I. (2008). An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia. Cognitive and Behavioral Neurology, 21(2), 98–103.PubMed

Janowsky, D. S., & Risch, C. (1979). Amphetamine psychosis and psychotic symptoms. Psychopharmacology, 65(1), 73–77.PubMed

Kishimoto, M., Ujike, H., Motohashi, Y., Tanaka, Y., Okahisa, Y., Kotaka, T., & Komiyama, T. (2008). The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biological Psychiatry, 63(2), 191–196.PubMed

Kittirattanapaiboon, P., Mahatnirunkul, S., Booncharoen, H., Thummawomg, P., Dumrongchai, U., & Chutha, W. (2010). Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug and Alcohol Review, 29(4), 456–461.PubMed

Mathias, S., Lubman, D. I., & Hides, L. (2008). Substance-induced psychosis: a diagnostic conundrum. Journal of Clinical Psychiatry, 69(3), 358–367.

McKetin, R. (2018). Methamphetamine psychosis: insights from the past. Addiction.

McKetin, R., McLaren, J., Lubman, D. I., & Hides, L. (2006). The prevalence of psychotic symptoms among methamphetamine users. Addiction, 101(10), 1473–1478.PubMed

McKetin, R., Hickey, K., Devlin, K., & Lawrence, K. (2010). The risk of psychotic symptoms associated with recreational methamphetamine use. Drug and Alcohol Review, 29(4), 358–363.PubMed

McKetin, R., Lubman, D. I., Lee, N. M., Ross, J. E., & Slade, T. N. (2011). Major depression among methamphetamine users entering drug treatment programs. Medical Journal of Australia, 195(3), S51–S55.

McKetin, R., Lubman, D. I., Baker, A. L., Dawe, S., & Ali, R. L. (2013). Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry, 70(3), 319–324.PubMed

McKetin, R., Dawe, S., Burns, R. A., Hides, L., Kavanagh, D. J., Teesson, M., & Saunders, J. B. (2016a). The profile of psychiatric symptoms exacerbated by methamphetamine use. Drug and Alcohol Dependence, 161, 104–109.PubMed

McKetin, R., Gardner, J., Baker, A. L., Dawe, S., Ali, R., Voce, A., & Lubman, D. I. (2016b). Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. Psychiatry Research, 238, 166–171.PubMed

McKetin, R., Baker, A. L., Dawe, S., Voce, A., & Lubman, D. I. (2017a). Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. Psychiatry Research, 251, 349–354.PubMed

McKetin, R., Degenhardt, L., Shanahan, M., Baker, A. L., Lee, N. K., & Lubman, D. I. (2017b). Health service utilisation attributable to methamphetamine use in Australia: patterns, predictors and national impact. Drug and Alcohol Review.

Medhus, S., Rognli, E. B., Gossop, M., Holm, B., Mørland, J., & Bramness, J. G. (2015). Amphetamine-induced psychosis: transition to schizophrenia and mortality in a small prospective sample. The American Journal on Addictions, 24(7), 586–589.PubMed

Niemi-Pynttäri, J. A., Sund, R., Putkonen, H., Vorma, H., Wahlbeck, K., & Pirkola, S. P. (2013). Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. Journal of Clinical Psychiatry, 74(1), 94–99.

van Os, J., Kenis, G., & Rutten, B. P. (2010). The environment and schizophrenia. Nature, 468(7321), 203–212.PubMed

Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013). Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug and Alcohol Dependence, 129(3), 167–179.PubMed

Papaleo, F., Yang, F., Garcia, S., Chen, J., Lu, B., Crawley, J., & Weinberger, D. (2012). Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Molecular Psychiatry, 17(1), 85–98.PubMed

Paparelli, A., Di Forti, M., Morrison, P. D., & Murray, R. M. (2011). Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Frontiers in Behavioral Neuroscience, 5.

Paulus, M. P., Tapert, S. F., & Schuckit, M. A. (2005). Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse. Archives of General Psychiatry, 62(7), 761–768.PubMed

Rognli, E. B., & Bramness, J. G. (2015). Understanding the relationship between amphetamines and psychosis. Current Addiction Reports, 2(4), 285–292.

Ross, R. G. (2006). Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. American Journal of Psychiatry, 163(7), 1149–1152.

Sato, M., Numachi, Y., & Hamamura, T. (1992). Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophrenia Bulletin, 18(1), 115–122.PubMed

Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., & Grant, I. (2007). Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychology Review, 17(3), 275–297.PubMed

Scott, N., Caulkins, J. P., Ritter, A., Quinn, C., & Dietze, P. (2015). High-frequency drug purity and price series as tools for explaining drug trends and harms in Victoria, Australia. Addiction, 110(1), 120–128.PubMed

Sekine, Y., Iyo, M., Ouchi, Y., Matsunaga, T., Tsukada, H., Okada, H., & Mori, N. (2001). Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. American Journal of Psychiatry, 158(8), 1206–1214.

Sekine, Y., Minabe, Y., Ouchi, Y., Takei, N., Iyo, M., Nakamura, K., & Yoshikawa, E. (2003). Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. American Journal of Psychiatry, 160(9), 1699–1701.

Shelly, J., Uhlmann, A., Sinclair, H., Howells, F. M., Sibeko, G., Wilson, D., & Temmingh, H. (2016). First-rank symptoms in methamphetamine psychosis and schizophrenia. Psychopathology, 49(6), 429–435.PubMed

Smith, M. J., Barch, D. M., & Csernansky, J. G. (2009). Bridging the gap between schizophrenia and psychotic mood disorders: relating neurocognitive deficits to psychopathology. Schizophrenia Research, 107(1), 69–75.PubMed

Srisurapanont, M., Ali, R., Marsden, J., Sunga, A., Wada, K., & Monteiro, M. (2003). Psychotic symptoms in methamphetamine psychotic in-patients. International Journal of Neuropsychopharmacology, 6(4), 347–352.

Srisurapanont, M., Arunpongpaisal, S., Wada, K., Marsden, J., Ali, R., & Kongsakon, R. (2011). Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(4), 959–964.PubMed

Starzer, M. S. K., Nordentoft, M., & Hjorthøj, C. (2017). Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. American Journal of Psychiatry.

Sulaiman, A. H., Said, M. A., Habil, M. H., Rashid, R., Siddiq, A., Guan, N. C., & Das, S. (2014). The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia. Comprehensive Psychiatry, 55(Suppl 1), S89–S94.PubMed

United Nations Office on Drugs and Crime. (2016). World drug report 2016. Retrieved from

Wang, L.-J., Lin, S.-K., Chen, Y.-C., Huang, M.-C., Chen, T.-T., Ree, S.-C., & Chen, C.-K. (2016). Differences in clinical features of methamphetamine users with persistent psychosis and patients with schizophrenia. Psychopathology, 49(2), 108–115.PubMed

Zhang, J.-P., Burdick, K. E., Lencz, T., & Malhotra, A. K. (2010). Meta-analysis of genetic variation in DTNBP1 and general cognitive ability. Biological Psychiatry, 68(12), 1126–1133.PubMedPubMedCentral

Zweben, J. E., Cohen, J. B., Christian, D., Galloway, G. P., Salinardi, M., Parent, D., & Iguchi, M. (2004). Psychiatric symptoms in methamphetamine users. The American Journal on Addictions, 13(2), 181–190.PubMed

Title: The Methamphetamine-Associated Psychosis Spectrum: a Clinically Focused Review
Authors: Shalini Arunogiri
Rebecca McKetin
Antonio Verdejo-Garcia
Dan I. Lubman
Publication date: 01-02-2020
Publisher: Springer US
Published in: International Journal of Mental Health and Addiction / Issue 1/2020
Print ISSN: 1557-1874
Electronic ISSN: 1557-1882
DOI: https://doi.org/10.1007/s11469-018-9934-4

2024 ASCO Annual Meeting

Springer Medicine

The Methamphetamine-Associated Psychosis Spectrum: a Clinically Focused Review

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Evaluation of the Selfitis Behavior Scale Across Two Persian-Speaking Countries, Iran and Afghanistan: Advanced Psychometric Testing in a Large-Scale Sample

Correction to: Gender Differences in the Association between Cyberbullying Victimization and Perpetration: the Role of Anger Rumination and Traditional Bullying Experiences

Public Knowledge of and Support for Supervised Injection Sites in a Metropolitan Canadian Region

Land-Based Intervention: a Qualitative Study of the Knowledge and Practices Associated with One Approach to Mental Health in a Cree Community

Personality Factors in Exercise Addiction: A Pilot Study Exploring the Role of Narcissism, Extraversion, and Agreeableness

Global Limit Setting as a Responsible Gambling Tool: What Do Players Think?